LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 9 of 497
Next
>>
>
201 to 225 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Mitoxantrone	0.04	uM	LJP6	3	C24	72	hr	1097	1382	3769	0.3666	0.1066
BT-20	MK2206	0.04	uM	LJP6	1	F06	72	hr	1097	3405	3769	0.9033	0.8636
BT-20	MK2206	0.04	uM	LJP6	2	F06	72	hr	1097	3164	3769	0.8394	0.7734
BT-20	MK2206	0.04	uM	LJP6	3	F06	72	hr	1097	3308	3769	0.8776	0.8273
BT-20	Neratinib	0.04	uM	LJP5	1	A18	72	hr	1097	2621	3769	0.6953	0.5702
BT-20	Neratinib	0.04	uM	LJP5	2	A18	72	hr	1097	2956	3769	0.7842	0.6956
BT-20	Neratinib	0.04	uM	LJP5	3	A18	72	hr	1097	3103	3769	0.8232	0.7506
BT-20	Nilotinib	0.04	uM	LJP5	1	N18	72	hr	1097	4017	3769	1.0656	1.0926
BT-20	Nilotinib	0.04	uM	LJP5	2	N18	72	hr	1097	4097	3769	1.0869	1.1225
BT-20	Nilotinib	0.04	uM	LJP5	3	N18	72	hr	1097	3777	3769	1.0020	1.0028
BT-20	Nintedanib	0.04	uM	LJP6	1	H06	72	hr	1097	3683	3769	0.9770	0.9676
BT-20	Nintedanib	0.04	uM	LJP6	2	H06	72	hr	1097	3458	3769	0.9174	0.8834
BT-20	Nintedanib	0.04	uM	LJP6	3	H06	72	hr	1097	3539	3769	0.9388	0.9137
BT-20	NU7441	0.04	uM	LJP5	1	C12	72	hr	1097	4382	3769	1.1625	1.2292
BT-20	NU7441	0.04	uM	LJP5	2	C12	72	hr	1097	3846	3769	1.0203	1.0286
BT-20	NU7441	0.04	uM	LJP5	3	C12	72	hr	1097	4131	3769	1.0959	1.1353
BT-20	Dactolisib	0.04	uM	LJP5	1	M18	72	hr	1097	1456	3769	0.3863	0.1343
BT-20	Dactolisib	0.04	uM	LJP5	2	M18	72	hr	1097	1381	3769	0.3664	0.1062
BT-20	Dactolisib	0.04	uM	LJP5	3	M18	72	hr	1097	1339	3769	0.3552	0.0905
BT-20	NVP-TAE684	0.04	uM	LJP6	1	K18	72	hr	1097	3798	3769	1.0076	1.0107
BT-20	NVP-TAE684	0.04	uM	LJP6	2	K18	72	hr	1097	3756	3769	0.9964	0.9949
BT-20	NVP-TAE684	0.04	uM	LJP6	3	K18	72	hr	1097	3806	3769	1.0097	1.0136
BT-20	Palbociclib	0.04	uM	LJP6	1	E18	72	hr	1097	2447	3769	0.6492	0.5051
BT-20	Palbociclib	0.04	uM	LJP6	2	E18	72	hr	1097	2381	3769	0.6316	0.4804
BT-20	Palbociclib	0.04	uM	LJP6	3	E18	72	hr	1097	2433	3769	0.6454	0.4999

|<
<<
Previous
Page 9 of 497
Next
>>
>
201 to 225 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)